Abstract
Methyl 2-methoxycarbonyl-3-phenylpropionate derivatives were prepared, and their inhibitory activities for angiotensin converting enzyme (ACE) were evaluated. The inhibitiory activity of methyl 3-{4-[2- [N-(4-methylbenzylphenyl)methyl,N-methylamino]ethoxy]phenyl} -2-methoxycarbonylpropionate (5b, IC50 = 0.0039 μM) and methyl 3-{4-[2-[N-bis(4-methoxy phenyl)methyl,N-methylamino]ethoxy]phenyl}-2- methoxycarbonylpropionate (5d, IC50 = 0.0027 μM) was higher than that of control drug captopril (IC50 = 0.0075 μM).
Keywords: ACE inhibitor, 2-methoxycarbonyl-3-phenyl propionate derivative, Hypertension
Letters in Organic Chemistry
Title: Methyl 2-Methoxycarbonyl-3-Phenylpropionate Derivatives: A New Type of Angiotensin Converting Enzyme Inhibitors
Volume: 3 Issue: 6
Author(s): Hui Guo, Bing Xie and Xiao-Hua Cai
Affiliation:
Keywords: ACE inhibitor, 2-methoxycarbonyl-3-phenyl propionate derivative, Hypertension
Abstract: Methyl 2-methoxycarbonyl-3-phenylpropionate derivatives were prepared, and their inhibitory activities for angiotensin converting enzyme (ACE) were evaluated. The inhibitiory activity of methyl 3-{4-[2- [N-(4-methylbenzylphenyl)methyl,N-methylamino]ethoxy]phenyl} -2-methoxycarbonylpropionate (5b, IC50 = 0.0039 μM) and methyl 3-{4-[2-[N-bis(4-methoxy phenyl)methyl,N-methylamino]ethoxy]phenyl}-2- methoxycarbonylpropionate (5d, IC50 = 0.0027 μM) was higher than that of control drug captopril (IC50 = 0.0075 μM).
Export Options
About this article
Cite this article as:
Guo Hui, Xie Bing and Cai Xiao-Hua, Methyl 2-Methoxycarbonyl-3-Phenylpropionate Derivatives: A New Type of Angiotensin Converting Enzyme Inhibitors, Letters in Organic Chemistry 2006; 3 (6) . https://dx.doi.org/10.2174/157017806777828484
DOI https://dx.doi.org/10.2174/157017806777828484 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?
Current Medicinal Chemistry Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences
Current Pharmaceutical Design Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Active Immunization Against Tumor Necrosis Factor-alpha Decreases Proinflammatory Cytokines, Oxidative Stress Mediators and Adhesion Molecules Risk Factors in Streptozotocin-induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets